已接种疫苗的慢性肝病与肝硬化患者突破性SARS-CoV-2感染结局:一项国家COVID队列协作研究
利用国家COVID队列协作(N3C)数据,纳入278,457例慢性肝病(CLD)患者,其中43,079例(15%)已接种疫苗、235,378例(85%)未接种。完全接种的CLD无肝硬化和肝硬化患者突破性感染发生率分别为5.4和4.9/1000人月。肝硬化患者中,未接种组与接种组30天内机械通气或死亡分别为15.2%和7.7%,完全接种与30天死亡调整风险比为0.34。
要点
- 完全接种的CLD无肝硬化与肝硬化患者突破性感染发生率分别为5.4和4.9/1000人月。
- 肝硬化患者中,未接种组与接种组30天内机械通气或死亡分别为15.2%和7.7%。
- 与未接种肝硬化患者相比,完全接种与30天死亡调整风险比为0.34。
核心结论
- 在N3C研究中,CLD患者伴与不伴肝硬化的突破性感染率相似。
- 完全接种与肝硬化CLD患者突破性感染后30天全因死亡风险降低66%相关。
- 这些结果为提高CLD人群疫苗接种率提供了额外动力。
研究设计与样本
- 利用国家COVID队列协作(N3C)数据,识别截至2022年1月15日接受SARS-CoV-2检测的CLD患者(伴或不伴肝硬化)。
- 共纳入278,457例CLD患者:43,079例(15%)已接种疫苗,235,378例(85%)未接种。
- 已接种的43,079例中,32,838例(76%)无肝硬化,10,441例(24%)伴肝硬化。
- 采用泊松回归估计突破性感染发生率,采用Cox生存分析关联接种状态与感染后30天全因死亡。
主要发现
- 完全接种的CLD无肝硬化与肝硬化患者突破性感染发生率分别为5.4和4.9/1000人月。
- 肝硬化患者中,未接种组68,048例中15%发生SARS-CoV-2感染,接种组10,441例中3.7%发生感染。
- 肝硬化患者SARS-CoV-2感染后30天机械通气或死亡:未接种组15.2%,接种组7.7%。
- 与未接种肝硬化患者相比,完全接种与30天死亡调整风险比为0.34。
关键数值与推荐
- 完全接种的CLD无肝硬化患者突破性感染发生率为5.4/1000人月。
- 完全接种的CLD肝硬化患者突破性感染发生率为4.9/1000人月。
- 肝硬化患者中,未接种组SARS-CoV-2感染比例为15%,接种组为3.7%。
- 肝硬化患者感染后30天机械通气或死亡:未接种组15.2%,接种组7.7%。
- 与未接种肝硬化患者相比,完全接种与30天死亡调整风险比为0.34。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Outcomes of breakthrough SARS-CoV-2 infections have not been well characterized in non-veteran vaccinated patients with chronic liver diseases (CLD). We used the National COVID Cohort Collaborative (N3C) to describe these outcomes. APPROACH AND RESULTS: We identified all CLD patients with or without cirrhosis who had SARS-CoV-2 testing in the N3C Data Enclave as of January 15, 2022. We used Poisson regression to estimate incidence rates of breakthrough infections and Cox survival analyses to associate vaccination status with all-cause mortality at 30 days among infected CLD patients. We isolated 278,457 total CLD patients: 43,079 (15%) vaccinated and 235,378 (85%) unvaccinated. Of 43,079 vaccinated patients, 32,838 (76%) were without cirrhosis and 10,441 (24%) with cirrhosis. Breakthrough infection incidences were 5.4 and 4.9 per 1000 person-months for fully vaccinated CLD patients without cirrhosis and with cirrhosis, respectively. Of the 68,048 unvaccinated and 10,441 vaccinated CLD patients with cirrhosis, 15% and 3.7%, respectively, developed SARS-CoV-2 infection. The 30-day outcome of mechanical ventilation or death after SARS-CoV-2 infection for unvaccinated and vaccinated CLD patients with cirrhosis were 15.2% and 7.7%, respectively. Compared to unvaccinated patients with cirrhosis, full vaccination was associated with a 0.34-times adjusted hazard of death at 30 days. CONCLUSIONS: In this N3C study, breakthrough infection rates were similar among CLD patients with and without cirrhosis. Full vaccination was associated with a 66% reduction in risk of all-cause mortality for breakthrough infection among CLD patients with cirrhosis. These results provide an additional impetus for increasing vaccination uptake in CLD populations.
引用
- Ge J, Digitale JC, Pletcher MJ, et al. Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study. Hepatology. 2023. PMID: 36799617. doi:10.1002/hep.32780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。